These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2932585)

  • 81. [Clinical study on the effect of intratumoral administration of OK-432 on breast cancer--anti-tumor immune response at the site of local injection].
    Hosokawa T
    Nihon Geka Gakkai Zasshi; 1991 May; 92(5):577-86. PubMed ID: 1831533
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
    Nishida Y; Sakakibara K; Kano T; Ohta M; Tomoda Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Endoscopic administration of OK-432 in gastric cancer].
    Inbe A; Sumii K; Haruma K; Uemura N; Tari A; Yoshihara M; Tokutomi T; Inaba Y; Sekito M; Ogoshi H
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):514-9. PubMed ID: 3954375
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Effects of OK-432 intraportal administration on cell-mediated immune responses].
    Minamimura T; Katsuyama S; Yamasaki K; Ookami H; Okamoto M; Masuyama K; Yamamoto K; Takemori S; Arai H; Sakamoto T; Tazawa K; Fujimaki M
    Gan To Kagaku Ryoho; 1997 Sep; 24(12):1867-9. PubMed ID: 9382553
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Su-polysaccharide skin test and immunotherapy with OK-432 in postoperative gastric cancer--the effect of a splenectomy].
    Saito H; Kikkawa H; Bando H; Sakatoku M; Hirano M; Tatsuzawa T
    Gan No Rinsho; 1988 Nov; 34(14):1965-8. PubMed ID: 3204664
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Peri-operative immunotherapy with OK-432.
    Yokota M; Tagawa Y; Okada D; Yasutake T; Mine Y; Ishikawa H; Miyashita K; Tomita M; Tabuchi S
    Biotherapy; 1990; 2(3):207-12. PubMed ID: 2206773
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients.
    Arinaga S; Akiyoshi T; Tsuji H
    Int J Immunopharmacol; 1988; 10(1):47-51. PubMed ID: 2966774
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Changes in cytokine levels in ascitic fluid after intraperitoneal administration of OK-432].
    Terashima M; Takagane A; Abe K; Kuboi M; Asahi H; Saito K
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1443-5. PubMed ID: 8373202
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Nursing of a patient with ascites being treated with OK-432].
    Yamashita I; Hidaka M; Ikegawa H; Yuhara K; Mori C
    Kango Gijutsu; 1989 Mar; 35(4):412-5. PubMed ID: 2754876
    [No Abstract]   [Full Text] [Related]  

  • 90. [Clinical investigation of intratumoral OK-432 administration].
    Shimada K; Tabuse K; Kono N; Katsumi M; Yamamoto H; Yamamoto Y; Endo A
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1844-9. PubMed ID: 6882008
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effect of immunochemotherapy on lymphocyte response of patients with gastrointestinal cancer.
    Mashiba H; Yoshinaga H; Matsunaga K; Gojobori M; Furusawa M
    J Surg Oncol; 1979; 12(3):275-9. PubMed ID: 502567
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Evaluation of various administration routes of the streptococcal preparation, OK-432, with regard to their in vivo effect by lymphocytes proliferation assay].
    Kimura Y; Toki H; Okabe K; Fujii M; Tamai M
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):95-100. PubMed ID: 3942400
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Studies on the enhancement of anti-tumor activity in patients with cervical cancer by local administration of OK-432].
    Yamada Y; Yamamoto K; Wakita K; Shiraki S; Noda K
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3427-31. PubMed ID: 3789753
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Treatment with streptococcal preparation (OK-432) suppresses anti-islet autoimmunity and prevents diabetes in BB rats.
    Satoh J; Shintani S; Oya K; Tanaka S; Nobunaga T; Toyota T; Goto Y
    Diabetes; 1988 Sep; 37(9):1188-94. PubMed ID: 3044884
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Adoptive immunotherapy against peritoneal metastases from stomach cancer--application of regional lymph node lymphocytes].
    Okino T; Kan N; Mise K; Nakanishi M; Satoh K; Yamasaki S; Teramura Y; Inoue K; Ohgaki K; Tobe T
    Nihon Gan Chiryo Gakkai Shi; 1990 Mar; 25(3):613-20. PubMed ID: 2351854
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immunological evaluation of a streptococcal preparation (OK-432) in treatment of bladder carcinoma.
    Kagawa S; Ogura K; Kurokawa K; Uyama K
    J Urol; 1979 Oct; 122(4):467-70. PubMed ID: 480487
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Case report: successful palliative treatment with intraperitoneal OK-432 injection for epithelioid haemangioendothelioma presenting with intractable ascites.
    Wei SC; Yang PM; Chen CH; Chu JS; Chen DS
    J Gastroenterol Hepatol; 1997 Jan; 12(1):39-43. PubMed ID: 9076621
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Search for immunobiological parameters predictive of clinical effects of OK-432 in patients with malignant ascites.
    Kataoka M; Hashimoto S; Nanjo M; Saito M; Sugawara Y; Yoshida T; Kamano T; Urabe M; Nishimura K; Sakakibara N
    Biotherapy; 1991; 3(3):193-201. PubMed ID: 1713048
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Intracavitary administration of OK-432 with subcutaneous priming for malignant ascites in a case of advanced renal cell carcinoma.
    Kageyama Y; Sakai Y; Arai G; Hyochi N; Suzuki M; Masuda H; Kawakami S; Hayashi T; Okuno T; Kobayashi T; Kihara K
    Int J Urol; 2002 Jan; 9(1):57-9. PubMed ID: 11972652
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Induction of endogenous tumor necrosis factor by OK-432 in ovarian cancer patients with ascites.
    Mori H; Itoh N; Yamada Y; Tamaya T
    Biotherapy; 1989; 1(3):123-31. PubMed ID: 2518374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.